Study Stopped
Lack of Funding
A Long-term Follow-up Study of Patients Who Received VOR33
1 other identifier
observational
10
2 countries
11
Brief Summary
VOR33 long-term follow-up (LTFU) study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2022
Typical duration for all trials
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2022
CompletedFirst Posted
Study publicly available on registry
April 4, 2022
CompletedStudy Start
First participant enrolled
April 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 28, 2025
CompletedJuly 29, 2025
May 1, 2025
3.1 years
March 24, 2022
July 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Long term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs).
Incidence of VOR33-related AEs/SAEs or deaths.
Years 1-15
Secondary Outcomes (1)
Long term efficacy of VOR33 in patients who participated in a VOR33 study in terms of persistence of CD33-negative hematopoiesis, overall survival (OS), and monthly relapse free survival (RFS).
Years 1-15
Study Arms (1)
Observational Cohort 1
All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
Interventions
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
Eligibility Criteria
All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
You may qualify if:
- A patient is included in this study if he/she:
- Has received any part of or all of a VOR33 infusion
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vor Biopharmalead
Study Sites (11)
University of California San Diego Moores Cancer Center
La Jolla, California, 92037, United States
Miami Cancer Institute
Miami, Florida, 33176, United States
National Institutes of Health, Clinical Center
Bethesda, Maryland, 20892, United States
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri, 63110, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, H1T2M4, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2022
First Posted
April 4, 2022
Study Start
April 15, 2022
Primary Completion
May 28, 2025
Study Completion
May 28, 2025
Last Updated
July 29, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share